|Videos|June 9, 2022

Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG

“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.

In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME